202 related articles for article (PubMed ID: 24406751)
21. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
22. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
[TBL] [Abstract][Full Text] [Related]
23. Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer.
Reckamp KL
Cancer Lett; 2012 Aug; 321(2):101-9. PubMed ID: 22306704
[TBL] [Abstract][Full Text] [Related]
24. Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?
Rossi A; Pasquale R; Esposito C; Normanno N
Cancer Treat Rev; 2013 Aug; 39(5):489-97. PubMed ID: 23022519
[TBL] [Abstract][Full Text] [Related]
25. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
Bunn PA; Thatcher N
Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
27. Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy.
Ng R; Loreto M; Lee R; Leighl NB
Lung Cancer; 2008 Aug; 61(2):262-5. PubMed ID: 18358559
[TBL] [Abstract][Full Text] [Related]
28. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
[TBL] [Abstract][Full Text] [Related]
29. [Second-line treatment and targeted therapy of advanced lung cancer].
Nakamura Y; Yamamoto N
Gan To Kagaku Ryoho; 2009 May; 36(5):710-6. PubMed ID: 19461168
[TBL] [Abstract][Full Text] [Related]
30. Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.
Dhillon S
Target Oncol; 2015 Jun; 10(2):303-10. PubMed ID: 25894578
[TBL] [Abstract][Full Text] [Related]
31. Targeted Therapies for Lung Cancer.
Stinchcombe TE
Cancer Treat Res; 2016; 170():165-82. PubMed ID: 27535394
[TBL] [Abstract][Full Text] [Related]
32. Clinical relevance of monoclonal antibodies in non small cell lung cancer.
Filipits M
J BUON; 2009 Sep; 14 Suppl 1():S147-52. PubMed ID: 19785057
[TBL] [Abstract][Full Text] [Related]
33. Targeted therapies in lung cancer.
Pirker R; Filipits M
Curr Pharm Des; 2009; 15(2):188-206. PubMed ID: 19149612
[TBL] [Abstract][Full Text] [Related]
34. Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.
Alden RS; Mandrekar SJ; Oxnard GR
Chin Clin Oncol; 2015 Sep; 4(3):37. PubMed ID: 26408304
[TBL] [Abstract][Full Text] [Related]
35. Nintedanib, a novel triple angiokinase inhibitor for the treatment of non-small cell lung cancer.
Noonan S; Man Wong K; Jimeno A
Drugs Today (Barc); 2015 Jun; 51(6):357-66. PubMed ID: 26261849
[TBL] [Abstract][Full Text] [Related]
36. The Role of the Antiangiogenetic Ramucirumab in the Treatment of Advanced Non Small Cell Lung Cancer.
Maione P; Sgambato A; Casaluce F; Sacco PC; Santabarbara G; Rossi A; Gridelli C
Curr Med Chem; 2017; 24(1):3-13. PubMed ID: 27855622
[TBL] [Abstract][Full Text] [Related]
37. Nintedanib in non-small cell lung cancer: from preclinical to approval.
Caglevic C; Grassi M; Raez L; Listi A; Giallombardo M; Bustamante E; Gil-Bazo I; Rolfo C
Ther Adv Respir Dis; 2015 Aug; 9(4):164-72. PubMed ID: 25855060
[TBL] [Abstract][Full Text] [Related]
38. Selumetinib for the treatment of non-small cell lung cancer.
Casaluce F; Sgambato A; Maione P; Sacco PC; Santabarbara G; Gridelli C
Expert Opin Investig Drugs; 2017 Aug; 26(8):973-984. PubMed ID: 28675058
[TBL] [Abstract][Full Text] [Related]
39. Molecular targeted therapy for early-stage non-small-cell lung cancer: will it increase the cure rate?
Martinez P; Martinez-Marti A; Navarro A; Cedrés S; Felip E
Lung Cancer; 2014 May; 84(2):97-100. PubMed ID: 24582269
[TBL] [Abstract][Full Text] [Related]
40. Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?
Bronte G; Passiglia F; Galvano A; Russo A
Expert Opin Biol Ther; 2016; 16(1):1-5. PubMed ID: 26235195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]